6 June 2006 in Nephrology Dialysis Transplantation
Opportunistic infections may assume rare and deceptive localizations, as illustrated by the following case.
3 March 2015 in DMW - Deutsche Medizinische Wochenschrift
CSChristoph Müller Philipps Sohn
Christoph Müller Philipps Sohn
Die Kalziphylaxie (kalzifizierende urämische Arteriolopathie, Englisch: calcific uremic arteriolopathy, CUA) ist eine seltene Erkrankung an der Schnittstelle zwischen Nephrologie, Dermatologie und Angiologie. Die CUA tritt meist bei erwachsenen chronischen Dialysepatienten auf, anekdotisch kommen auch Fälle bei Patienten ohne relevante Nierenerkrankung vor. Klinisch ist die CUA charakterisiert durch eine klassische kaskadenartige Entwicklung, die mit stark schmerzhaften oberflächlichen Missempfindungen beginnt und sich über Livedo-artige Hautveränderungen begleitet von einer derben Induration zu offenen Ulzerationen weiterentwickeln kann. Der histopathologische Befund ist von einer Pannikulitis mit oft zirkumferenten Kalzifikationen innerhalb der Wand von kutanen Arteriolen gekennzeichnet, was gemeinsam mit Endothelabschilferungen zu Gefäßokklusionen und Nekrosen führen kann. Die Prognose der CUA ist von einer hohen Morbidität und Mortalität gekennzeichnet. Die Ätiologie der Erkrankung ist nur teilweise aufgeklärt. Auffallend ist, dass ein hoher Anteil an betroffenen Patienten unter einer Therapie mit Vitamin-K-Antagonisten zur oralen Dauerantikoagulation stand. In der Therapie fehlen bisher evidenzbasierte Standards. Konsequente Schmerztherapie und ein gutes Wundmanagement sind Eckpfeiler der Therapie. Registerstudien wie das deutsche Kalziphylaxieregister (www.calciphylaxis.net) können helfen, Risikofaktoren aufzudecken, Expertenwissen auszutauschen, lokale Behandlungszentren zu identifizieren und bis zur Etablierung von studienbasierter Therapieevidenz zumindest eine „good clinical practice“ zu definieren. Calciphylaxis (calcific uremic arteriolopathy, CUA) is a rare disease at the interface of nephrology, dermatology and cardiovascular medicine. CUA typically occurs in chronic dialysis patients. However, anecdotal reports also exist about cases in patients without relevant kidney disease. Clinically CUA is characterized by the stepwise development of superficial painful sensations and cutaneous lesions similar to livedo reticularis. Skin necrosis and ulceration represent the full-blown, “late” clinical picture. Panniculitis and circumferential calcification of cutaneous arterioles dominate the histological picture together with endothelial detachment. The prognosis of CUA is poor due to high morbidity and mortality largely resulting from underlying cardiovascular disease or septicemia. The aetiology of CUA is incompletely understood. Previous oral anticoagulation with vitamin K antagonists is considered as a risk factor. Unfortunately, evidence-based therapeutic options are absent, since controlled treatment trials have not been conducted yet. Long-term pain and wound management are mandatory. In the absence of controlled prospective trials registry studies such as the German CUA registry (www.calciphylaxis.net) support data collecting and analysis upon good clinical practice and may stimulate exchange of expertise and networking.
27 August 2018 in Nephrology Dialysis Transplantation
The clinical management of chronic kidney disease-mineral bone disorder (CKD-MBD) remains extremely challenging, partially due to difficulties in defining high-risk phenotypes based on serum biomarkers. We evaluated the prevalence and outcomes of 27 mutually exclusive CKD-MBD phenotypes in a large, multi-national cohort of chronic dialysis patients over a 5-year follow-up study. In this historical cohort study, we enrolled all haemodialysis patients registered in EuCliD® on 1 July 2011 across 28 Europe, the Middle East and Africa (EMEA) and South American countries. We created 27 mutually exclusive phenotypes based on combinations of serum parathyroid hormone (PTH), phosphorus (P) and calcium (Ca) 6-month averages (L, low; T, target; H, high). We tested the association between CKD-MBD phenotypes and 5-year mortality and hospitalization risk by outcome risk score-adjusted proportional hazard regression. We enrolled 35 721 eligible patients. Eastern European and South American countries generally achieved poorer CKD-MBD control when compared with Western European countries (prevalence ratio: 0.79; P < 0.001). There were 15 795 deaths [126.7 deaths/1000 person-years; 95% confidence interval (CI) 124.7-128.7]; 18 014 had at least one hospitalization (203.9 hospitalizations/1000 person-years; 95% CI 201.0-206.9); the incidence of the composite endpoint was 280.0 events/1000 person-years (95% CI 276.6-283.5). In the fully adjusted model, relative mortality risk ranged from hazard ratio (HR) = 1.07 (PTH/Ca/P: TLT) to HR = 1.59 (PTH/Ca/P: LTL), whereas the relative composite endpoint risk ranged from HR = 1.07 (PTH/Ca/P: TTH) to HR = 1.36 (PTH/Ca/P: LTL). We identified several CKD-MBD phenotypes associated with reduced hospitalization-free survival and increased mortality. Ranking of relative risk estimates or excess events concurs in informing healthcare priority setting.
11 October 2025 in Clinical Pharmacology & Therapeutics
Pharmacogenomics (PGx) helps to explain variability in drug response, including adverse drug reactions. Functional variants in genes affecting drug absorption, distribution, metabolism, and excretion (ADME) have been described. Despite PGx guidelines (e.g., CPIC and DPWG) enabling genotype‐guided drug and dose selection, preemptive implementation remains challenging due to various issues including standardized result communication and integration into electronic health record (EHR) systems. We implemented PGx testing as well as drug–drug interaction (DDI) screening in a German academic hospital and assessed their impact on physicians, general practitioners (GPs), and patients. A novel PGx workflow was established using a 60‐genetic variant panel. CPIC/DPWG guideline‐based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system. Medication profiles and questionnaires evaluated PGx‐based decisions 3 months post‐discharge. Among 255 patients, 95% had at least one actionable PGx variant, most commonly affecting statins, 5‐fluorouracil, irinotecan, and pantoprazole. Actionable recommendations were provided in 21.5%, with hospital physicians modifying treatment subsequently in 75.5%. We identified 57 clinically significant DDIs, including PGx drugs in 21%. GPs maintained optimized treatment in 77% of those patients with a medication change initiated during hospitalization. One in 10 patients discussed results with their GPs. GPs favored PGx for future prescriptions and requested training. We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.
1 September 2011 in Kidney International Supplements